The upcoming report from Jazz Pharmaceuticals (JAZZ) is expected to reveal quarterly earnings of $5.26 per share, indicating an increase of 7614.3% compared to the year-ago period. Analysts forecast revenues of $1.01 billion, representing an increase of 3.7% year over year.Over the last 30 days, there has been an upward revision of 1.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over ...

Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.  Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial expe ...

DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 full year and fourth quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 888 350 4423Irela ...

Redx Pharma PLC (AIM:REDX) said it is sellling its KRAS inhibitor programme to Nasdaq-listed Jazz Pharma Inc in a deal with a headline value of US$880 million. Under the terms of the transaction, Redx will receive an upfront US$10 million followed by US$870 million in development, regulatory, and sales milestone payments. It will also get royalties on any future sales. Its KRAS inhibitor programme targets one of the most challenging areas in cancer research. Mutations in the KRAS gene are prevalent across v ...

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net salesPreclinical program expands Jazz's pipeline of targeted oncology therapiesDUBLIN and ALDERLEY PARK, United Kingdom, Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat ...

Ackun/iStock via Getty Images Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) have traded flat to somewhat lower since my November 2022 article and this was largely in line with what the average biotech stock was doing until early November of last year, the time when biotech stocks began to recover and Jazz's share price made no progress. YCharts My view at the time was that the stock was worth approximately $190 per share and more if the company could execute well against its 2025 and long-term goals of reach ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale ...

Call Start: 16:30 January 1, 0000 5:52 PM ET Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q3 2023 Earnings Conference Call November 08, 2023, 16:30 ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Renee Gala - President & COO Robert Iannone - EVP & Global Head, Research & Development Kim Sablich - EVP & GM, US Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Jason Gerberry - Bank of America Merrill Lynch Ami Fadia - Needham & Company Jeremy Jacoby - Tru ...

BRAF Mutant Mutant RAS or RTK CLASS 1 CLASS 2 CLASS 3 Driven B-RAF B-RAF Mutated B-RAF Mutated mEGFR / mRTK V600E Driven Dimer Driven RAS Driven mRAS RAS RAS RAS B-RAF B-RAF C-RAF / WT C-RAF / B-RAF C-RAF / C-RAF V600E D594X B-RAF A-RAF A-RAF G469X A-RAF MEK MEK MEK MEK Growth Inhibition Growth Inhibition Growth Inhibition Cell Growth Growth Inhibition █ 1st Gen. B-RAF V600E Inhibitor ● Pan-RAF Inhibitor JZP815 Examine antitumor activities across patient mutation subsets | --- | --- | |--------------------- ...